Article citationsMore>>

Bolognesi, M.L., Rosini, M., Andrisano, V., Bartolini, M., Minarini, A., Tumiatti, V. and Melchiorre, C. (2009) MTDL Design Strategy in the Context of Alzheimer’s Disease: From Lipocrine to Memoquin and Beyond. Current Pharmaceutical Design, 15, 601-613.
https://doi.org/10.2174/138161209787315585

has been cited by the following article:

• TITLE: Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia

  AUTHORS: Sameena E. Tanwir, Ajay Kumar

  KEYWORDS: Alzheimer, β Amyloid, Tau, Acetylcholinesterase, Amyloid Precursor Protein, Plaques, Tangles, Neurodegeneration

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.9 No.1, March 13, 2019

  ABSTRACT: Alzheimer’s disease (AD) is a neurodegenerative disease distinguished by progressive cognitive deterioration along with declining activities of daily living and behavioral changes. It is the commonest type of pre-senile and senile dementia. Many new therapeutic strategies have been developed in the last few years. We aimed at reviewing the evidence supporting these new therapeutic targets, including anti-amyloid and anti-Tau strategies. This review is focused on important future direction in investigation of potential therapeutic targets for AD drug discovery. Medical advances have improved treatment of many diseases but still there is a need to establish new tools for early diagnosis of AD. A thorough comprehensive understanding of the unexplored mechanism can ameliorate the diagnostic and therapeutic management of AD. There have been several disease-modifying therapeutic strategies for AD in the last few years and are presently at various phases of investigation. Few of them have shown promising results, but their safety and efficacy need to be further explored.